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Morphine and Hydromorphone-Induced Hyperalgesia in a Hospice
Patient
Abstract
Abstract Opioids including morphine and hydromorphone are widely used for control of moderate to severe
pain and dyspnea in hospice and palliative care patients. Accumulation of the active morphine-3-glucuronide
(M3G) and hydromorphone-3-glucuronide (H3G) metabolites is one proposed mechanism for the
development of neuroexcitatory effects including allodynia and opioid-induced hyperalgesia (OIH). We
report the case of a 43-year-old female hospice patient with metastatic non-small cell lung cancer who initially
developed allodynia following morphine administration and again following administration of
hydromorphone. The allodynia resolved both times following the discontinuation of the opioid and rotation
to a different opioid regimen. Potential opioid-induced neuroexcitatory treatment options include opioid
rotation to an agent with inactive metabolites, use of adjuvant pain medications for opioid-sparing effects,
management of undesired symptoms (e.g., myoclonus), or increasing opioid clearance with intravenous (IV)
fluids. Although the incidence is not well defined in the literature, hospice and palliative care clinicians should
suspect OIH in patients with allodynia and/or hyperalgesia, especially when repeated dose escalations do not
improve analgesia or pain escalates following opioid dose titration.
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Abstract
Opioids including morphine and hydromorphone are widely used for control of moderate to severe pain and
dyspnea in hospice and palliative care patients. Accumulation of the active morphine-3-glucuronide (M3G) and
hydromorphone-3-glucuronide (H3G) metabolites is one proposed mechanism for the development of neu-
roexcitatory effects including allodynia and opioid-induced hyperalgesia (OIH). We report the case of a 43-year-
old female hospice patient with metastatic non-small cell lung cancer who initially developed allodynia fol-
lowing morphine administration and again following administration of hydromorphone. The allodynia resolved
both times following the discontinuation of the opioid and rotation to a different opioid regimen. Potential
opioid-induced neuroexcitatory treatment options include opioid rotation to an agent with inactive metabolites,
use of adjuvant pain medications for opioid-sparing effects, management of undesired symptoms (e.g., myoc-
lonus), or increasing opioid clearance with intravenous (IV) fluids. Although the incidence is not well defined in
the literature, hospice and palliative care clinicians should suspect OIH in patients with allodynia and/or
hyperalgesia, especially when repeated dose escalations do not improve analgesia or pain escalates following
opioid dose titration.
Introduction
Morphine and hydromorphone are frequently usedopioids for moderate to severe pain and dyspnea in
hospice and palliative care patients. Morphine and hydro-
morphone are classified within the phenanthrene opioid class
and aremetabolized via glucuronidation to activemetabolites
including morphine-3-glucuronide (M3G) and hydro-
morphone-3-glucuronide (H3G), respectively, which are
renally eliminated.1–4 These metabolites do not provide an-
algesia, but they cross the blood-brain barrier (BBB) and their
accumulation may produce neuroexcitatory adverse effects
including agitation, myoclonus, seizures, hallucinations,
allodynia, and hyperalgesia.2–5 Allodynia results when non-
noxious stimuli are perceived as painful, whereas hyper-
algesia occurs when a patient experiences disproportionate
responses to painful stimuli.6 Pain associated with opioid-
induced hyperalgesia (OIH) frequently occurs in a different
area of the body, has a dissimilar quality compared with the
original nociceptive stimulus, and may be accompanied by
myoclonus.7,8 One feature of OIH is a paradoxical increase in
pain following opioid administration. Although the incidence
of OIH is not defined in the literature, it should be suspected
when repeated dose escalations do not improve analgesia or a
pain exacerbation results from opioid dose titration.9 Given
the potential for declining renal function with advanced ill-
ness and aggressive opioid use that is often needed to manage
pain and dyspnea, hospice and palliative care patients may be
at increased risk for opioid metabolite accumulation with
subsequent hyperalgesia and allodynia. Hospice and pallia-
tive care clinicians should recognize signs and symptoms
associated with OIH to avoid subsequent opioid titrations
that may worsen pain or lead to further neurotoxicity.
We describe the case of a hospice patient who developed al-
lodynia initially frommorphine then with hydromorphone to
illustrate the importance of recognizing this adverse effect
in clinical practice and to discuss potential management
strategies.
Case Description
A 43-year-old female patient diagnosed stage IIIB non-
small cell lung cancer with bilateral rib metastases was
admitted to home hospice. Her past medical history was
significant for osteoarthritis, depression, and anxiety. Upon
hospice admission the patient reported neuropathic pain from
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her lower back extending down her legs and somatic pain in
her knees. Based on the results of magnetic resonance imaging
(MRI) of the lumbar spine, her back pain was thought to be
related to degenerative changes at L5–S1. Approximately 5
months after hospice enrollment the patient was rotated from
fentanyl patches to morphine sulfate extended release 100mg
twice daily due to inadequate analgesia. Fifteen days after the
patient was started on morphine, she experienced new onset
generalized pain with tactile stimulation that escalated into
severe pain to light touch and the inability to move without
excruciating pain. The patient rated her pain as a 6/10 on a 0
to 10 scale when lying completely still and a ‘‘15 to 20’’/10
with movement. Her pain medications consisted of morphine
sulfate ER 100mg orally twice daily, morphine sulfate 60mg
sublingually every 2 hours as needed for pain (approximately
2 doses/day), gabapentin 1200mg orally 3 times daily, and
ibuprofen 800mg orally 3 times daily. Recent renal function
labs were not available in this outpatient setting, so new labs
were ordered to evaluate kidney function. Morphine sulfate
and ibuprofen were discontinued. The gabapentin dose was
decreased and ibuprofen was stopped due to suspected renal
impairment, although the results of the patient’s renal func-
tion testing were later found to be within normal limits. The
hospice team followed up with the patient’s pain physician
and her opioid regimen was changed to oxycodone ER 40mg
orally 3 times daily and hydromorphone 8 to 16mg orally
every 2 hours as needed for pain. Her allodynia resolved over
the next week.
Sixteen days later, the patient reported an escalation in her
back painwith radiation to her legs withmovement. She rated
this pain as 4/10 when lying completely still and 8 to 9/10
with movement. Nortriptyline 50mg orally at bedtime was
added for additional neuropathic pain coverage and gaba-
pentin was increased to 1200mg orally 3 times daily. Nine
days later, the patient’s allodynia reemerged and peripheral
edema was noted. Gabapentin was tapered and carbamaze-
pine 200mg orally twice a day was initiated as an alternative
neuropathic pain treatment. The patient’s breakthrough hy-
dromorphone use gradually increased over the 25 days
postopioid rotation, although exact outpatient dose and fre-
quency of administration was not consistently documented.
After the 25-day period the patient reported increased vivid
dreams with the sensation of crickets crawling on her. A
maximum oral hydromorphone dose of 16mg, 6 to 7 times
daily was noted at this time by the hospice nurse. The patient
was transferred to the hospital for initiation of a fentanyl
patient controlled analgesia (PCA) and monitoring. Three
days later she was discharged home on an intravenous (IV)
fentanyl PCA with a 100mcg/hour basal rate and bolus dose
of 25mcg IV every 15 minutes as needed for pain. The only
remaining pain the patient reported after fentanyl PCA initi-
ation was mild somatic knee pain.
Discussion
Both animal and human studies have reported M3G- and
H3G-associated OIH and allodynia. Wright and colleagues
evaluated the excitatory effects and comparative potency of
M3G and H3G after intracerebroventricular (IVC) adminis-
tration.3 Rats received ICV H3G, M3G, or artificial cerebro-
spinal fluid (aCSF) injections and were observed for
behavioral changes. Results showed H3G administration
produced dose-dependent excitatory behavior induction
similar to M3G administration. Smith found that ICV ad-
ministration ofM3Gwas a potent antagonist of morphine and
M6G analgesia.10 Rats administered 2.5 lg or 3lg ICV M3G
15 minutes prior to or after 20 lg ICV morphine were ob-
served to have an increase in the incidence of allodynia, hy-
peralgesia, excessive grooming, tremor, wet dog shakes,
opioidergic system activation indicated by raised tails (Straub
tail), seizures, and death compared with rats administrated
morphine 20lg ICV alone. Results showed rats given M3G
10mg intraperitoneal (IP) 30 to 40 minutes prior to morphine
1.5mg IP had significantly reduced analgesic response com-
pared with morphine 1.5mg IP alone (p < 0.05).
Sjogren and coworkers described a case series of cancer
patients who developed hyperalgesia or allodynia with
morphine use that resolved following opioid rotation.8 The
first case was a 19-year-old female with gliosarcoma who was
titrated up to 20 g per day of morphine IV over a 14-month
period. She experienced hyperalgesia, myoclonus, and allo-
dynia that resolved with rotation to oral methadone. The
second case described a 55-year-old female breast cancer pa-
tient with bone pain. This patient was being treated with
60mg of sustained-release morphine daily when she began to
experience severe pain and allodynia from wearing clothing.
She was switched to oral ketobemidone 40mg per day, and
the pain she previously experienced with touch was allevi-
ated. A third case was that of a 68-year-old woman with
breast cancer and bone metastases who developed allodynia
while taking 1000mg of sustained-release oral morphine
daily. After rotation to a subcutaneous sufentanil infusion at
1.2mg per day, the patient’s allodynia resolved. The fourth
case report was that of a 10-year-old boy with an astrocytoma
and cerebral infiltrationwho experienced allodynia on 750mg
per day of oral morphine equivalent. The patient’s allodynia
disappeared within 2 days of methadone rotation.
In addition to the above case series, Sjogren et al. reported
the cases of six patients, four with cancer-related pain and two
with chronic, nonmalignant pain who were receiving mod-
erate to high dose morphine via IV, oral, or intrathecal (IT)
routes who developed hyperalgesia, allodynia, and/or
myoclonus.11 Each of the patients’ symptoms resolved upon
rotation to an alternative opioid without active metabolites as
such oral methadone, continuous IV sufentanil, or IT fentanyl.
The authors obtained plasma and CSF M3G, morphine-6-
glucoride (M6G), and morphine levels from each patient to
determine if elevated levels correlated with hyperalgesia,
allodynia, and/or myoclonus. Unfortunately, the laboratory
results were highly variable and no significant pattern was
established. In each case once the morphine was stopped and
was substituted with an alternative opioid, the patient’s al-
lodynia disappeared, which is similar to what we observed in
our patient.
Parisod and colleagues describe a case of allodynia after a
single IT morphine dose in a 66-year-old male paraplegic
patient.12 The patient experienced persistent neuropathic pain
from a previous spinal cord injury below T8 that was refrac-
tory to IT fentanyl, IV lidocaine, T7-T10 laminectomy, lumbar
sympathetic blocks, and a transcutaneuous electrical nerve
stimulation (TENS) unit along with oral clonazepam, valproic
acid, carbamazepine, gabapentin, mexiletine, amitriptyline,
doxepin, clonidine, and paracetamol with dextropropox-
yphene. Within 2 hours of receiving a 0.5mg IT morphine
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bolus dose the patient reported allodynia over the T6 and T7
dermatomes on his right side. Four days later the patient was
given another 0.2-mg intrathecal injection of morphine after
which the allodynia recurred.
In a study by Smith et al. 14 opioid-tolerant cancer patients
with inadequate analgesia from oral or subcutaneous mor-
phine received ICV morphine and CSF and plasma samples
were drawn for morphine, M3G, and M6G concentrations
to determine whether intraspinal morphine levels cause
neuroexcitory adverse effects including hyperalgesia.13 It was
found that plasma and CSF concentrations of M3G decreased
after the change to ICV morphine, whereas the CSF concen-
trations of morphine increased approximately 50-fold. Pa-
tients reported pain relief with the ICV morphine and a
decrease in excitatory side effects implicating morphine me-
tabolites may be responsible for adverse events and tolerance
to systemic morphine.
Several case reports describe OIH in humans who received
hydromorphone. Patel et al. describe the case of a 55-year-old
male with nonobstructive hypertropic cardiomyopathy who
was receiving IV hydromorphone for acute left-sided chest
pain and dyspnea.14 After administration of 4mg IV hydro-
morphone on hospital day 1, the patient’s wife reported two
episodes of ‘‘jerking’’ movements that increased in frequency
with dose escalation on day 2. Electroencephalogram (EEG)
results on day 3 showed no seizure activity and the patient’s
renal function was stable with an estimated creatinine clear-
ance (CrCl) ranging from 72mL/minute to 79mL/minute
throughout the hospitalization. On day 3 the patient’s my-
oclonus resolved after IV hydromorphone was stopped and
the patient was rotated to oral oxycodone.
Chung and colleagues report an episode of hydromorphone-
induced neurotoxicity in a 61-year-old male with stage IV
transitional cell bladder carcinoma and prostate adenocarci-
noma.15 The patient was admitted to the hospital for an exac-
erbation of left hip pain with radiation down the left leg and
was initiated on a hydromorphone PCA. Over the next 8 days,
his IV hydromorphone dose escalated from 23mg/day to
1890mg/day with subsequent new-onset hyperalgesia, trem-
ors, confusion, and hallucinations. He was rotated to oral
methadone 60mg every 6 hours and oxycodone 10mg orally
every 3 hours for breakthrough pain. The patient reported
improved pain and myoclonus resolution 2 days after metha-
done rotation. His methadone dose was decreased to 40mg
orally every 8 hours at 48 hours and improvement in mental
status by 72 hours was noted.
Forero et al. note a case of OIH and opioid neurotoxicity in
a 52-year-old male with chronic low back pain from disk
herniation.16 Over the course of 17 years, the patient received
numerous interventions for his poorly controlled pain in-
cluding a L5–S1 laminectomy, nonsteroidal anti-inflammatory
drugs, acetaminophen, oral opioids, nerve blocks, medial
branch ablations, physiotherapy, intrathecal morphine, and a
spinal cord stimulator. An intrathecal hydromorphone pump
was placed at year 11 and the dose was titrated to 12mg/day
over the next 6 years. During year 17, the patient experienced
new-onset generalized burning and aching pain that he rated
as 9/10. He was admitted to the hospital for a suspected dis-
connection between the intrathecal catheter and implanted
pump. A pump revision was completed under general anes-
thesia and the patient was started on a hydromorphone PCA.
Postoperatively he developed severe lower back spasms and
pain with bilateral radiation down his legs and feet. These
symptoms increased with the administration of 12mg of IV
hydromorphone and 10mg IV morphine over 30 minutes. No
evidence of a catheter tip granuloma was observed on com-
puted tomography (CT) scan. The patient emergently received
a 15-mg IV ketamine bolus (0.25mg/kg/bolus) with resolu-
tion of his pain and spasms. A ketamine infusion at 3mg/hour
(50mcg/kg/hour) was started and his IT hydromorphone
dose was decreased to 2.5mg/day. The ketamine infusion was
stopped 12 hours later without additional spasms or reemer-
gence of the generalized aching and burning pain. The patient
was discharged home 30 hours after his postoperative pain
exacerbation on 2.5mg/day of IT hydromorphone with con-
tinued back pain at a level the patient considered acceptable.
Potential opioid-induced neuroexcitatory treatment op-
tions include opioid rotation, adjuvant pain medications (e.g.,
ketamine) for opioid-sparing effects, managing unwanted
symptoms such as hallucinations or myoclonus, or increasing
opioid clearance with administration of IV fluids.5 The pri-
mary intervention for my case patient allodynia with both
morphine and hydromorphone was opioid rotation to pro-
mote metabolite excretion of the previous offending agent.
Because the hospice team had incomplete hospital medical
records, it is unknown if the patient received IV fluids to
promote H3G metabolite excretion or a neuroleptic agent to
manage the patient’s associated delusions. Converting to one-
fourth to one-half the equianalgesic dose is recommended
during opioid rotation to a structurally different opioid.17,18
During the first allodynia occurrence, the patient was
converted to scheduled extended-release oxycodone and as
needed oral hydromorphone. Utilizing an equianalgesic
conversion ratio of 7.5mg oral hydromorphone to 20mg oral
oxycodone, the equianalgesic oxycodone equivalent of the
patient’s oral hydromorphone breakthrough use (96mg to
112mg oral hydromorphone = 256mg to 299mg oral oxyco-
done) exceeded the patient’s scheduled oxycodone regimen.
Oxycodone produced greater analgesic effects comparedwith
morphine in healthy adult volunteers with experimentally
induced hyperalgesia.19 The potential for oxycodone metab-
olites to produce allodynia and hyperalgesia is not established
in the medical literature. It was also noted that when hydro-
morphone was discontinued and the patient was rotated
to fentanyl, an agent within the phenylpiperidine opioid
class and with no active metabolites, the patient’s allodynia
resolved and my patient who was discussed in the case
description section had improved analgesia.
Chronic opioid use is also proposed to cause OIH through
inhibition of the central glutamate transporter system result-
ing in increased glutamate availability to the N-methyl-D-
asparate (NMDA) receptors and NMDA receptor activa-
tion.20–23 Givenmethadone’s inactivemetabolites andNMDA
receptor antagonist properties, rotation to methadone would
also have been a reasonable pharmacologic option. Un-
fortunately, our case patient would not accept a methadone
trial due to a previous episode of suspected pulmonary in-
flammation. Fentanyl and methadone maintain analgesia
without producing active metabolites. Additional allodynia
treatment options include initiation of neuropathic pain ad-
juvant medications, for example, ketamine, nortriptyline,
carbamazepine, and gabapentin.
Both M3G and H3G metabolite accumulation can induce
allodynia and hyperalgesia.3,8,10–12 It has also been described
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that when opioid rotation occurs to an agent with inactive
metabolites allodynia or hyperalgesia may resolve.2,24 As far
as we know, this is the first case of OIH secondary to both
morphine and hydromorphone reported in a hospice patient,
which resolved following opioid rotation. Hospice and palli-
ative care clinicians should recognize OIH signs and symp-
toms in order to avoid subsequent opioid titrations that may
contribute to the cycle of increasing pain or distressing allo-
dynia.
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